Immunogenicity and safety of an inactivated hepatitis A vaccine administered concomitantly with diphtheria-tetanus-acellular pertussis and haemophilus influenzae type B vaccines to children less than 2 years of age.

@article{Nolan2006ImmunogenicityAS,
  title={Immunogenicity and safety of an inactivated hepatitis A vaccine administered concomitantly with diphtheria-tetanus-acellular pertussis and haemophilus influenzae type B vaccines to children less than 2 years of age.},
  author={Terence M Nolan and Henry L. Bernstein and Mark M Blatter and Kenneth W. Bromberg and Fernando Guerra and William Thomas Kennedy and Michael E. Pichichero and Shelly David Senders and Andrew F. Trofa and Alix Collard and Diane C Sullivan and Dominique J Descamps},
  journal={Pediatrics},
  year={2006},
  volume={118 3},
  pages={
          e602-9
        }
}
OBJECTIVE The availability of a hepatitis A virus vaccine for infant and early childhood immunization could reduce the transmission of hepatitis A virus in the United States. This study evaluated the immunogenicity and safety of a hepatitis A virus vaccine (Havrix, GlaxoSmithKline Biologicals, Rixensart, Belgium) administered concomitantly with diphtheria-tetanus-acellular pertussis and Haemophilus influenzae type b vaccines to children < 2 years. METHODS In this open, comparative… CONTINUE READING